BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 33358543)

  • 21. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
    Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
    Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.
    Stabile A; Barletta F; Motterle G; Pellegrino F; Sorce G; Mazzone E; Scuderi S; Cirulli GO; Cucchiara V; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1137-1142. PubMed ID: 33941867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiparametric MRI and
    Privé BM; Israël B; Janssen MJR; van der Leest MMG; de Rooij M; van Ipenburg JA; Jonker M; Peters SMB; de Groot M; Zámecnik P; Hoepping A; Bomers JG; Gotthardt M; Sedelaar JPM; Barentsz JO; van Oort IM; Nagarajah J
    Radiology; 2024 May; 311(2):e231879. PubMed ID: 38771185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic Resonance Imaging-targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer.
    Alkema NG; Hoogeveen SFJS; Cauberg ECC; Witte LPW; van 't Veer-Ten Kate M; de Boer E; Hoogland MAM; Blanker MH; Boomsma MF; Steffens MG
    Eur Urol Open Sci; 2022 Oct; 44():125-130. PubMed ID: 36185584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Rajwa P; Sari Motlagh R; Mostafaei H; Quhal F; Laukhtina E; Aydh A; König F; Pallauf M; Pradere B; Ceci F; Baltzer PAT; Hacker M; Rasul S; Karakiewicz PI; Araki M; Nasu Y; Shariat SF
    Eur Urol Oncol; 2022 Aug; 5(4):390-400. PubMed ID: 35715320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
    Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
    Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
    Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
    World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suboptimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy.
    Karsiyakali N; Ozgen MB; Ozveren B; Akbal C; Dincer A; Durak H; Turkeri L
    Urology; 2021 Feb; 148():217-223. PubMed ID: 32871139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.
    Lee CH; Vellayappan B; Tan CH
    Br J Radiol; 2022 Mar; 95(1131):20210509. PubMed ID: 34520694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
    Venderink W; van Luijtelaar A; Bomers JGR; van der Leest M; Hulsbergen-van de Kaa C; Barentsz JO; Sedelaar JPM; Fütterer JJ
    Eur Urol; 2018 Mar; 73(3):353-360. PubMed ID: 28258784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
    Kato D; Ozawa K; Takeuchi S; Kawase M; Kawase K; Nakai C; Takai M; Iinuma K; Nakane K; Kato H; Matsuo M; Suzui N; Miyazaki T; Koie T
    Curr Oncol; 2021 Mar; 28(2):1294-1301. PubMed ID: 33809967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.
    Israël B; Leest MV; Sedelaar M; Padhani AR; Zámecnik P; Barentsz JO
    Eur Urol; 2020 Apr; 77(4):469-480. PubMed ID: 31767492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 40. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.